Temisis
Private Company
Funding information not available
Overview
Temisis Therapeutics is a Paris-based, private biotech advancing novel small molecules for inflammatory diseases, with a primary focus on psoriasis. Its lead asset, TEM-1657, has shown in preclinical models to achieve rapid symptom remission and complete healing without the side effects, such as skin thinning, associated with current corticosteroids or oral therapies like apremilast. The company is positioned to address a significant unmet need in a large global market, though it remains at a preclinical stage with no disclosed clinical data, partnerships, or financing details.
Technology Platform
Proprietary small molecules targeting the Th17/IL-23 inflammatory axis, designed to separate efficacy from side effects like skin atrophy.
Opportunities
Risk Factors
Competitive Landscape
Competes in the crowded psoriasis market against topical corticosteroids/calcipotriene, oral small molecules (apremilast, deucravacitinib), and numerous injectable biologics (anti-TNF, IL-17, IL-23 inhibitors). Key differentiation claims are a superior safety profile versus steroids (no skin thinning) and oral PDE4 inhibitors (fewer side effects).